Breast cancer risk can be reduced in women with the use of selective estrogen receptor modifiers (SERMs) such as tamoxifen[1] and raloxifene [2]or with the use of aromatase inhibitors (AIs)[3]. This evidence concerns the gene ESR1 and breast carcinoma.